Mogamulizumab versus investigator’s choice of chemotherapy regimen in relapsed/refractory adult T-cell leukemia/lymphoma

Mogamulizumab, a humanized defucosylated anti-C-C chemokine receptor 4 monoclonal antibody, has been approved in Japan for the treatment of C-C chemokine receptor 4-positive adult T-cell leukemia/lymphoma (ATL). This phase II study evaluated efficacy and safety of mogamulizumab in ATL patients with...

Descripción completa

Detalles Bibliográficos
Autores principales: Phillips, Adrienne A., Fields, Paul A., Hermine, Olivier, Ramos, Juan C., Beltran, Brady E., Pereira, Juliana, Wandroo, Farooq, Feldman, Tatyana, Taylor, Graham P., Sawas, Ahmed, Humphrey, Jeffrey, Kurman, Michael, Moriya, Junji, Dwyer, Karen, Leoni, Mollie, Conlon, Kevin, Cook, Lucy, Gonsky, Jason, Horwitz, Steven M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ferrata Storti Foundation 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6518882/
https://www.ncbi.nlm.nih.gov/pubmed/30573506
http://dx.doi.org/10.3324/haematol.2018.205096

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6518882/
https://www.ncbi.nlm.nih.gov/pubmed/30573506
http://dx.doi.org/10.3324/haematol.2018.205096

Ejemplares similares